Other languages Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.65 ^USD	+3.31%		-0.14%	-9.18%

Mar. 13	Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Feb. 06	Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	Feb. 06
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	Jan. 18
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries	Jan. 12
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe	Jan. 12
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 08
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	Jan. 05
Deciphera Pharmaceuticals Insider Sold Shares Worth $259,256, According to a Recent SEC Filing	23-10-31
Deciphera Pharmaceuticals' Q3 Net Loss Widens, Revenue Rises; Says Phase 3 Tumor Drug Trial Met Primary Endpoint	23-10-30
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor	23-10-30
Deciphera Pharmaceuticals Q2 Loss Narrows, Revenue Advances	23-08-09
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023	23-08-03
Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock at the 2023 American Society of Clinical Oncology Annual Meeting	23-05-25
Deciphera Pharmaceuticals Q1 Loss Narrows, Revenue Rises; Shares Fall	23-05-03
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03
Insider Sell: Deciphera Pharmaceuticals	23-03-23
Deciphera Pharmaceuticals Says FDA Designates Qinlock as Breakthrough Therapy to Treat Gastrointestinal Stromal Tumor	23-03-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Other languages

Filters